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RESEARCH
A randomized controlled trial to determine 
whether beta-hydroxy-beta-methylbutyrate 
and/or eicosapentaenoic acid improves 
diaphragm and quadriceps strength in critically 
Ill mechanically ventilated patients
Gerald S. Supinski1, Paul F. Netzel1, Philip M. Westgate2, Elizabeth A. Schroder1, Lin Wang1 and 
Leigh Ann Callahan1*  
Abstract 
Background: Intensive care unit acquired weakness is a serious problem, contributing to respiratory failure and 
reductions in ambulation. Currently, there is no pharmacological therapy for this condition. Studies indicate, however, 
that both beta-hydroxy-beta-methylbutyrate (HMB) and eicosapentaenoic acid (EPA) increase muscle function in 
patients with cancer and in older adults. The purpose of this study was to determine whether HMB and/or EPA admin-
istration would increase diaphragm and quadriceps strength in mechanically ventilated patients.
Methods: Studies were performed on 83 mechanically ventilated patients who were recruited from the Medical 
Intensive Care Units at the University of Kentucky. Diaphragm strength was assessed as the trans-diaphragmatic 
pressure generated by supramaximal magnetic phrenic nerve stimulation (PdiTw). Quadriceps strength was assessed 
as leg force generated by supramaximal magnetic femoral nerve stimulation (QuadTw). Diaphragm and quadriceps 
thickness were assessed by ultrasound. Baseline measurements of muscle strength and size were performed, and 
patients were then randomized to one of four treatment groups (placebo, HMB 3 gm/day, EPA 2 gm/day and HMB 
plus EPA). Strength and size measurements were repeated 11 days after study entry. ANCOVA statistical testing was 
used to compare variables across the four experimental groups.
Results: Treatments failed to increase the strength and thickness of either the diaphragm or quadriceps when com-
pared to placebo. In addition, treatments also failed to decrease the duration of mechanical ventilation after study 
entry.
Conclusions: These results indicate that a 10-day course of HMB and/or EPA does not improve skeletal muscle 
strength in critically ill mechanically ventilated patients. These findings also confirm previous reports that diaphragm 
and leg strength in these patients are profoundly low. Additional studies will be needed to examine the effects of 
other anabolic agents and innovative forms of physical therapy.
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Background
Critically ill patients develop significant muscle weak-
ness of both the diaphragm, the major muscle of breath-
ing, and limb muscles. Diaphragm weakness influences 
intensive care unit (ICU) outcomes, such that patients 
with weak diaphragms have a much higher mortality and 
a longer duration of mechanical ventilation than patients 
with stronger diaphragms [1–6]. In addition, limb mus-
cle weakness has negative consequences for critically ill 
patients [7, 8]. Limb muscle weakness persists long after 
ICU discharge, reduces long-term exercise performance, 
and decreases the ability of patients to perform activities 
of daily living [7–12].
Importantly, recent studies indicate that both beta-
hydroxy-beta-methylbutyrate (HMB) and eicosapen-
taenoic acid (EPA) improve muscle function in cancer 
patients and in older adults [13–16]. HMB is thought to 
exert these effects by inhibition of protein degradation, 
increases in protein synthesis, and reductions in muscle 
cell apoptosis, while EPA is thought to reduce protein 
degradation and to increase mitochondrial biogenesis 
[17, 18]. There has been, however, only limited study of 
the effects on these agents on muscle properties in the 
critically ill [19, 20] and no previous examination of the 
effects on strength of intensive care unit patients.
The purpose of the present study, therefore, was to 
determine whether HMB and/or EPA administration 
would also increase diaphragm and quadriceps strength 
in mechanically ventilated patients. To accomplish this 
task, we measured both diaphragm and quadriceps 
strength by determining, respectively, pressure and force 
generation in response to supramaximal magnetic stimu-
lation of the nerves (phrenic and femoral) to these mus-
cles in a cohort of mechanically ventilated ICU patients. 
In addition, we used ultrasound to assess the thickness of 
the diaphragm and the quadriceps (i.e. the rectus femo-
ris and vastus intermedius). Baseline measurements of 
muscle strength and size were performed; then patients 
were randomized to one of four treatment groups (pla-
cebo, HMB 3  g/day, EPA 2  g/day and HMB plus EPA). 
Strength and size measurements were repeated 11  days 
after study entry. The primary endpoint of the study 
was to determine whether HMB, EPA, or the combina-
tion of these agents improved diaphragm or quadriceps 
muscle strength. Secondary endpoints were to deter-
mine whether these agents increased diaphragm and 
quadriceps muscle thickness, and/or reduced the time 
required to wean patients from mechanical ventilation.
Methods
Patient selection
Approval to conduct this research was obtained from the 
University of Kentucky Institutional Review Board (IRB). 
Consent for inclusion in these studies was obtained 
from all subjects and/or their surrogates. Inclusion into 
the study was considered for all adult patients requiring 
mechanical ventilation for more than 48 h for respiratory 
failure in one of the University of Kentucky adult medi-
cal ICUs. Subjects were included regardless of sex, race, 
or age. Subjects were excluded: (a) if the physician caring 
for the patient determined that the patient was too unsta-
ble to tolerate these measurements; or if the patient; (b) 
was receiving high dose pressors (more than 15 mcg/min 
of norepinephrine or more than 15 mg/kg/min of dopa-
mine), (c) required > 80%  FiO2 or > 15 cm  H2O of PEEP, 
(d) had a cardiac pacemaker or implanted defibrillator, 
(e) received neuromuscular blocking agents within the 
48 h preceding testing, (f ) had a history of a preexisting 
neuromuscular disease, (g) had recent variceal bleeding, 
(h) was pregnant, (i) was incarcerated, (j) was institu-
tionalized, or (k) if the attending physician thought that 
the patient was terminal and would have care withdrawn 
within 7 days.
Study protocol
After informed consent was obtained, we:
(a) Measured magnetic stimulated diaphragm twitch 
pressure (PdiTw), quadriceps twitch strength 
(QuadTw), diaphragm thickness, quadriceps thick-
ness, lung mechanics (respiratory system compli-
ance, airway resistance), and performed a chart 
review,
(b) Randomized patients to enteral treatment with 
either: placebo (30 ml of salt water solution, 1.5 g of 
amino acids and 1 ml of corn oil every 12 h), eicosa-
pentaenoic acid (EPA; 30 ml of salt water, 1.5 g of 
amino acids and 1000  mg EPA every 12  h), beta-
hydroxy-beta-methylbutyrate (HMB; 30  ml of salt 
water solution, 1500 mg HMB and 2 ml of corn oil 
Trial registration: ClinicalTrials.gov, NCT01270516. Registered 5 January 2011, https:// clini caltr ials. gov/ ct2/ show/ NCT01 
270516? term= Supin ski& draw= 2& rank=4.
Keywords: Diaphragm weakness, Respiratory failure, Mechanical ventilation, Limb muscle weakness, Beta-hydroxy-
beta-methylbutyrate, Eicosapentaenoic acid
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every 12  h), or both HMB and EPA (30  ml of salt 
water, 1500 mg HMB and 1000 mg EPA every 12 h).
(c) Continued placebo or drug treatments for 10 days, 
and
(d) On day 11, repeated measurements of PdiTw, 
QuadTw, diaphragm thickness, and quadriceps 
thickness.
Randomization of patients was performed by the 
Research Pharmacy Service at the University of Ken-
tucky following a randomization design formulated by 
the study statistician (Dr. Westgate). As part of this rand-
omization, patients were stratified by age so that approxi-
mately equal numbers of patients greater than 55  years 
of age and less than 55 years of age would be placed into 
the four treatment arms. The Research Pharmacy service 
then arranged for delivery of the drugs to the critical care 
services caring for patients. Nurses administering the 
drugs and all investigators obtaining consent and making 
study measurements were blinded as to patient treatment 
arm assignments: this blinding continued for the dura-
tion of the study.
There are several reasons we chose a course of 10 days 
of therapy with HMB and/or EPA. First, animal experi-
ments suggest that even short courses of these medica-
tions (48  h) should be effective [28, 29], so we thought 
that extremely long treatments would not be needed. Sec-
ond, the majority of patients in our hospital remain in the 
ICU for approximately 10–14  days and many are trans-
ferred to long-term ventilator units after this time point 
if they cannot be weaned from mechanical ventilation. 
For this reason, we thought it was important that a 10 day 
course of therapy would be effective; if a drug treatment 
takes substantially longer than 10 days to improve muscle 
function, we do not believe it would change the trajectory 
of mechanical ventilation use in most ICUs in the United 
States.
In accordance with the IRB approved protocol, research 
personnel did not make any clinical decisions regarding 
the management of patients while being treated in the 
intensive care unit.
Determination of transdiaphragmatic twitch pressure 
generation (PdiTw)
Diaphragm strength was assessed by determining trans-
diaphragmatic twitch pressure (PdiTw) in response to 
bilateral anterior magnetic stimulation of the phrenic 
nerves (BAMPS) as previously described in detail [1, 2]. 
In brief, two sterile balloon tipped catheters (Cooper Sur-
gical, Turnbull, CT) were passed through the nose and 
one catheter was placed in the stomach and the other 
placed in the esophagus [1, 2]. Patients were then allowed 
to breathe quietly for 10 min. Magnetic coils attached to 
MagStim 200 stimulators were placed bilaterally over the 
phrenic nerves, and simultaneous supramaximal pulses 
were delivered to elicit twitch transdiaphragmatic pres-
sure (i.e. PdiTw), while transiently occluding the circuit 
connecting the endotracheal tube to the ventilator. A 
minimum of five twitches were recorded at 100% field 
stimulation, and additional twitches were performed at 
reduced magnetic field strengths (60–90%). PdiTw was 
recorded as the average of the best three measurements 
in response to 100% levels of magnetic stimulation. All 
the measurements of PdiTw were carried out by Dr. 
Supinski and Dr. Netzel.
Diaphragm thickness
Right hemidiaphragm thickness was measured over the 
zone of apposition using two dimensional B mode and M 
mode ultrasound and a high-frequency linear array probe 
(10  MHz) [21]. The transducer was positioned over the 
mid-axillary line between the 7th and 8th ribs or 8th and 
9th ribs, and respiratory variation in diaphragm thick-
ness was assessed by recording diaphragm signals in M 
mode using the ultrasound caliper utility to measure dia-
phragm thickness at end expiration. Average end expira-
tory diaphragm thickness was calculated from three sets 
of measurements. All the measurements of diaphragm 
thickness were carried out by Dr. Supinski and Dr. Netzel.
Measurement of quadriceps twitch strength (QuadTw)
Quadriceps twitch force was measured using magnetic 
stimulation of the femoral nerve using modifications 
as previously reported in detail [22, 23]. Prior to meas-
urement, patient remained inactive in bed for 20  min. 
A quadriceps support was placed under the right leg, 
positioned with the knee immediately over the apex 
of the apparatus. To record force, a transducer (Omega 
Engineering, Inc., Norwalk, CT) was placed around the 
lower leg at the ankle. A figure of eight coil was placed 
over the femoral nerve, with the coil powered by a Mag-
Stim 200 stimulator (Jali Industries, Ma USA). Coil place-
ment was adjusted to achieve maximum force generation, 
followed by sequentially stimulating at field strengths 
between 60 and 100%. QuadTw was recorded as the aver-
age of the best three measurements in response to 100% 
levels of magnetic stimulation. All the measurements of 
quadriceps force were carried out by Dr. Supinski and Dr. 
Netzel.
Quadriceps thickness
We determined right quadriceps thickness by measuring 
the thickness of the vastus intermedius (VIM) and rec-
tus femoris (RF) at its widest extent (i.e. in the anterior-
to posterior orientation, determined as the distance from 
the adipose tissue-muscle interface to the intermuscular 
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interface for each muscle). The measurements were 
assessed at 50% of the distance between the lateral con-
dyle of the femur and the greater trochanter. Total 
quadriceps thickness was recorded as the average of the 
sum of VIM and RF from the three best measurements 
obtained. All the measurements of quadriceps thickness 
were carried out by Dr. Supinski and Dr. Netzel.
Clinical parameters
Clinical parameters including: age, gender, diagnoses, 
vital signs, duration of mechanical ventilation prior to 
PdiTw measurement, mechanical ventilation mode,  FiO2, 
tidal volume and rate, and most recent arterial blood gas 
values, were collected as close as possible to the time of 
determination of PdiTw and QuadTw. We also recorded 
the sequential organ failure assessment (SOFA) score 
and Charlson Comorbidity Score (CCS) for each patient. 
Finally, since the time required to wean patients from 
mechanical ventilation is thought to be influenced by res-
piratory muscle function [1, 2, 5, 6], we also assessed the 
effect of the various treatment regimens on the duration 
of mechanical ventilation after study entry.
Nutrition, physical therapy, patient sedation, 
and mechanical ventilation weaning regimens
All the patients in this study were provided physical ther-
apy and occupational therapy in keeping with the stand-
ard regimens employed by the physical and occupational 
therapy department of the University of Kentucky hos-
pitals. In addition to these sessions, bedside nurses pro-
vided range-of-motion exercises to patients each shift. 
Detailed descriptions of the physical therapy protocols, 
as well as the nutritional protocol and mechanical ven-
tilation weaning protocol, are provided in the Additional 
file 1 (Methods.docx).
Statistical analysis
A power analysis performed prior to initiation of the 
study estimated that we needed approximately 18 
patients/group (total of 72) to detect a 30% improvement 
in muscle strength between the placebo group and a drug 
treatment group with an assumed standard deviation of 
24.5%, a power of 0.85, and an alpha level of 0.05. Subject 
recruitment was ended when we achieved initial meas-
urements of strength in 73 patients.
Baseline comparisons (Tables 1 and 2) were conducted 
via one-way ANOVA. ANCOVA testing was used to 
compare changes in key variables measured before and 
after drug treatment for the four experimental groups, 
including diaphragm twitch (natural log), diaphragm 
thickness (natural log), quadriceps force and quadriceps 
thickness, with correction for the corresponding initial 
measure and several potential confounding variables 
(age, sex, Charlson Comorbidity Score, Sequential Organ 
Failure Score (SOFA), duration of mechanical ventilation 
prior to randomization into the study). A similar analysis 
was conducted to compare the natural log of mechani-
cal ventilation durations. A p value of less than 0.05 was 
taken as indicating statistical significance for compari-
sons. Analyses were conducted in SAS version 9.4 (SAS 
Institute, Cary, NC, USA).
Results
Patient characteristics
We assessed 345 patients for study eligibility of which 262 
were excluded because of failure to meet study inclusion 
and exclusion criteria (see Fig. 1). Consent was obtained 
in the remaining 83 patients. Not every parameter could 
be successfully completed in each subject. Ten patients 
either withdrew before measurements could be made or 
there were technical issues (e.g. massive obesity) that pre-
cluded any measurement of diaphragm and quadriceps 
strength. Adequate measurements of initial diaphragm 
or quadriceps parameters were made in the remaining 
73 patients but technical issues prevented acquisition 
of complete data sets in several patients. Technically 
adequate (i.e. achieving supramaximal twitches) base-
line diaphragm strength measurements (PdiTw) were 
obtained in 64 of 73 patients and technically adequate 
baseline quadriceps strength (QuadTw) were achieved in 
71 of 73 patients. As a result, the present report includes 
baseline PdiTw data for 64 patients and baseline QuadTw 
data for 71 patients.
Patients recruited to this study were severely ill, with 
mean sequential organ failure (SOFA) scores of 7.0 for 
control (placebo) patients, 7.7 for EPA treated, 6.7 for 
HMB and 8.1 for patients treated with both EPA and 
HMB. SOFA scores were not significantly different 
across the four groups. Patient groups also had signifi-
cant chronic medical comorbidities, with mean Charl-
son Comorbidity Scores (CCS) of 2.9–4.0 for the four 
experimental groups. CCS were not different across the 
four groups. Patients had mean durations of previous 
mechanical ventilation of 7.3–9.2  days prior to study 
entry, and all had failed at least one attempt to wean from 
mechanical ventilation.
Several other patient characteristics are presented in 
Table 1. There were no significant differences in age, vital 
signs, mechanical ventilator settings, or lung mechanics 
(i.e. compliance and resistance) across the four experi-
mental groups. The mean number of treatment doses 
that patients in the four groups received ranged from 17 
to 19, indicating that there was good compliance with 
administration of medications to all groups of experi-
mental subjects.
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Table 1 Patient demographics
Bold was used to highlight the groups, means and P values
Italics represents the n = number of subjects per group and the 95% confidence interval
CI = Confidence interval, SOFA = sequential organ failure score, CCS = Charlson comorbidity score, MV = mechanical ventilation, BP = blood pressure, mm 
Hg = millimeters of mercury, F = Fahrenheit,  FiO2 = fraction of inspired oxygen, PEEP = positive end expiratory pressure,  H2O = water, PT = physical therapy, 
OT = occupational therapy
a Respiratory system static compliance (ml/cm  H2O)
b Airway resistance (cm  H2O/liter/second)
Control EPA HMB HMB + EPA P values
(n = 20) (n = 17) (n = 18) (n = 18)
Mean Mean Mean Mean
(95% CI) (95% CI) (95% CI) (95% CI)
Age (years) 55.5 52.9 61.2 56.2 0.384
(47.7–63.1) (46.0–59.7) (54.0–68.4) (49.7–62.7)
Weight (kg) 86.5 89.3 93.7 83.8 0.714
(76.0–96.9) (75.8–102.8) (81.3–106.0) (67.6–99.9)
SOFA 7.0 7.7 6.7 8.1 0.619
(5.3–8.7) (6.0–9.4) (5.3–8.1) (6.1–10.1)
CCS 4.0 3.0 3.6 2.9 0.483
(2.7–5.3) (1.6–4.4) (2.4–4.7) (1.9–3.9)
Prior MV duration (days) 9.2 8.8 7.5 7.3 0.875
(4.7–13.6) (5.1–12.4) (4.0–11.0) (3.1–11.5)
Systolic BP (mm Hg) 119 115 120 119 0.836
(111–127) (106–124) (112–129) (110–128)
Diastolic BP (mm Hg) 68 61 63 68 0.344
(61–74) (53–69) (56–70) (62–73)
Heart rate (beats/min) 87.3 90.9 82.4 93.6 0.264
(78.5–96.0) (81.8–100.1) (74.4–90.5) (84.9–102.2)
Temp (°F) 99.1 99.2 99.2 98.4 0.134
(98.5–99.8) (98.6–99.8) (98.5–99.9) (97.8–98.9)
Respirations (breaths/min) 22.3 23.1 20.0 21.5 0.289
(19.4–25.1) (20.2–26.1) (17.2–22.1) (18.9–24.1)
FiO2 0.43 0.52 0.44 0.45 0.149
(0.39–0.48) (0.44–0.58) (0.38–0.49) (0.41–0.49)
PEEP (cm  H2O) 5.9 8.3 6.2 6.4 0.056
(5.1–6.7) (6.2–10.4) (4.9–7.5) (5.1–7.8)
Static  compliancea 26.0 23.0 23.2 24.0 0.673
(21.3–30.8) (19.1–26.9) (20.1–26.3) (19.5–28.4)
Airway  resistanceb 10.7 10.0 14.8 12.5 0.128
(8.7–12.7) (6.9–13.1) (10.1–19.5) (9.9–15.2)
Number of doses 19.0 18.2 17.8 17.0 0.465
(18.1–19.9) (15.7–20.7) (15.9–19.7) (14.8–19.2)
Number of PT-OT sessions 2.6 2.6 1.8 2.9 0.590
(1.3–3.9) (1.5–3.7) (0.8–2.8) (1.4–4.3)
Primary Enteral Enteral Enteral Enteral
Nutrition route Tube feeding Tube feeding Tube feeding Tube feeding
Degree of dependence Independent 55% Independent 59% Independent 61% Independent 67%
Assistance 45% Assistance 41% Assistance 39% Assistance 33%
Main diagnoses Respiratory failure 35% Respiratory failure 53% Respiratory failure 56% Respiratory failure 50%
Sepsis 45% Sepsis 41% Sepsis 44% Sepsis 56%
Pneumonia 60% Pneumonia 53% Pneumonia 33% Pneumonia 39%
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More detailed information, on a subject-by-subject 
basis, is provided on-line in the Additional file 2 (Detailed 
Subject Information.docx). This table provides diagnoses, 
activity levels prior to admission, and reason for admis-
sion for each participant in this study. Almost all patients 
were admitted for medical diagnoses, with a high per-
centage in all four groups having diagnoses of infections. 
The percentage of patients transferred to the MICU 
from other services was similar for the four groups. In 
addition, length of stay prior to ICU transfer was simi-
lar for the four groups, averaging means of 2.5 days (95% 
CI 0.42–4.48), 2.8 days (95% CI − 0.97 to 6.53), 3.5 days 
(95% CI 0.76–6.24), and 1.1 days (95% CI − 0.34 to 2.56), 
respectively, for Control, EPA, HMB, and HMB + EPA 
groups (p = 0.595).
Physical therapy and caloric intake
Average durations of physical and occupational therapy 
per day are provided in Fig.  2 for patients randomized 
to the four groups of treatments. Unfortunately, the 
ability of physical and occupational therapists to exer-
cise patients in this study was limited by several factors, 
including medical instability, the requirement for off-
unit diagnostic testing, and the need for time consuming 
ICU procedures. These events resulted in cancellation 
of planned therapy sessions, and as a result, the average 
combined durations of physical and occupational therapy 
achieved in the four groups (Fig. 2) were shorter than the 
goal of 10 min per day.
All patients received enteral tube feedings and all 
patients also received protein supplements. The level of 
caloric and protein intakes were similar in all four treat-
ment groups (Figs.  3 and 4) and were within the range 
found to produce acceptable outcomes in ICU patients 
[24].
Diaphragm strength and thickness
Patients had profoundly weak diaphragms at study 
entry, as shown in Table  2. Diaphragm strength, as 
assessed by measurement of diaphragm twitch genera-
tion (PdiTw) in response to bilateral supramaximal mag-
netic stimulation of the phrenic nerves (i.e. the BAMPS 
technique) was extremely low in the four experimental 
groups, with average levels less than 7 cm  H2O in all four 
groups. This value is similar to that previously reported 
for MICU patients [1–4] but much lower than values 
observed in normal healthy subjects (which average 
29 cm  H2O, with a lower limit of normal of 15 cm  H2O) 
[1, 21, 25]. ANCOVA analyses found no significant dif-
ferences in adjusted mean changes between the four 
arms for either PdiTw (p = 0.89) or thickness (p = 0.50). 
Importantly, we found that PdiTw did not improve sig-
nificantly in response to any of the therapeutic regimens 
(i.e. EPA, HMB, or HMB + EPA) employed in this study 
(Fig.  5). We also found that diaphragm thickness was 
Table 2 Initial patient diaphragm and quadriceps characteristics
Bold was used to highlight the groups, means and P values
Italics represents the n = number of subjects per group and the 95% confidence interval
CI = Confidence interval, PdiTw shown in cm  H2O, QuadTw in Newtons, cm = centimeters, n = number of measurements per treatment arm-as indicated elsewhere in 
the text, every measurement could not be obtained from each subject. Data represent actual values obtained for each measurement
Control EPA HMB HMB + EPA
Mean Mean Mean Mean P values
(95% CI) (95% CI) (95% CI) (95% CI)
n n n n
Diaphragm strength (PdiTw) 7.4 5.4 3.7 5.8 0.050
4.7–10.1 4.2–6.5 2.5–4.9 4.0–7.6
n = 19 n = 15 n = 15 n = 15
Diaphragm thickness (cm) 0.26 0.27 0.26 0.25 0.878
0.23–0.29 0.24–0.30 0.23–0.30 0.22–0.28
n = 19 n = 15 n = 16 n = 17
Quadriceps strength (QuadTw) 5.9 5.2 4.6 5.1 0.913
3.1–8.6 1.9–8.6 2.8–6.4 3.0–7.3
n = 20 n = 17 n = 16 n = 18
Quadriceps thickness (cm) 2.8 3.3 3.1 2.6 0.327
2.4–3.3 2.7–3.8 2.6–3.6 1.9–3.3
n = 20 n = 16 n = 15 n = 18
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similar in the four experimental groups at study initia-
tion (Table  2). Moreover, diaphragm thickness did not 
increase in response to EPA, HMB or the combination of 
HMB + EPA (Fig. 5).
Quadriceps strength and thickness
Patients also manifested severe quadriceps weakness 
at the time of recruitment into the current study. As 




¨ Not meeting inclusion criteria 
(n=255)
¨ Declined to participate (n=3)









Lost to follow up:
Transfer to LTAC (n=1)
Care withdrawn (n=2)
Patient withdrew from 
study (n=0)
Allocated to Control 
Arm
(n=20)

























Lost to follow up:
Transfer to LTAC (n=1)
Data lost (n=1)
Care withdrawn (n=1)
Patient withdrew from 
study (n=1)
Lost to follow up:
Transfer to LTAC (n=1)
Went home (n=1)
Care withdrawn (n=3)








Lost to follow up:




Patient withdrew from 
study (n=0)





Fig. 1 Consort diagram. We initially screened 345 patients and consent was obtained from 83. Of these, 10 failed to complete initial measurements 
of diaphragm size and strength, with the remaining 73 patients randomized to the four treatment arms. Several patients were lost or withdrew 
during the treatment administration phase in each study group (i.e. 3 in the control (placebo), 4 in the EPA, 5 in the HMB and 5 in the HMB + EPA 
arm) due to death, transfer, or request to be removed from the study. In the remaining patients, we obtained data examining changes in diaphragm 
strength (PdiTw), diaphragm size, quadriceps strength (QuadTw) and quadriceps size between initial, pre-treatment and final, post-treatment 
measurements
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was less than 5 Newtons in all four treatment arms of 
the current study. In contrast, the quadriceps twitch 
force reported for healthy subjects in a recent study is 
several fold higher [22]. The initial quadriceps twitch 
force was similar, however, for patients in the four 
treatment groups of the present report. ANCOVA 
analyses found no significant differences in adjusted 
mean changes between the four arms for either quadri-
ceps twitch force (p = 0.46) or thickness (p = 0.43). As 
Fig. 2 The average duration of physical therapy per day (top panel) 
and the average duration of occupational therapy per day (bottom 
panel) is presented for the four groups of patients included in the 
current study, i.e. placebo treated control patients, patients treated 
with EPA, patients treated with HMB, and patients treated with the 
combination of HMB and EPA. Both figures present data for individual 
subjects included in the four experimental groups. Group means for 
the experimental groups are presented as vertical bars (top of bar) 
and error bars indicate the 95% CI of the mean for the experimental 
groups. The mean duration of physical therapy per day was 3.23 min 
(95% CI 1.43–5.04), 4.72 min (95% CI 2.12–7.31), 2.12 min (95% CI 
0.48–3.77), and 3.27 min (95% CI 1.48–5.06), respectively, for Control, 
EPA, HMB, and HMB + EPA groups (p = 0.278). The mean duration of 
occupational therapy per day was 2.8 min (95% CI 1.4–4.2), 3.1 min 
(95% CI 1.5–4.7), 1.5 min (95% CI 0.2–2.5), and 3.2 min (95% CI 
1.5–4.9), respectively, for Control, EPA, HMB, and HMB + EPA groups 
(p = 0.267)
Fig. 3 Prescribed caloric intakes, actual delivered caloric intakes, and 
calories/kg/day are presented for the four experimental groups. The 
prescribed caloric intake per day was 1526 kcal (95% CI 1325–1727), 
1284 kcal (95% CI 994–1574), 1426 kcal (95% CI 1223–1629), and 
1276 kcal (95% CI 1022–1530), respectively for Control, EPA, HMB, and 
HMB + EPA groups (p = 0.337). The mean caloric intake per day was 
1207 kcal (95% CI 952–1462), 1010 kcal (95% CI 742–1279), 1096 kcal 
(95% CI 894–1298), and 912 kcal (95% CI 663–1160), respectively 
for Control, EPA, HMB, and HMB + EPA groups (p = 0.296). The mean 
caloric intake/Kg per day was 15.1 (95% CI 11.5–18.7), 12.1 (95% CI 
8.9–15.3), 13.0 kcal (95% CI 10.0–16.0), and 14.5 kcal (95% CI 9.3–19.7), 
respectively for Control, EPA, HMB, and HMB + EPA groups (p = 0.641). 
As a result, there were no significant differences in caloric intake 
(Kcal/Day) or caloric intake normalized to body weight (Kcal/Kg) 
between the four groups
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a result, no treatments improved quadriceps twitch 
force over time or increased quadriceps thickness 
(Fig. 6).
Duration of mechanical ventilation
As shown in Fig.  7, there was no significant difference 
in the time required to wean patients from mechanical 
ventilation across the experimental groups in this study. 
Specifically, neither EPA, HMB, or the combination of 
EPA + HMB reduced the duration of mechanical ventila-
tion compared to placebo.
Discussion
Summary of major findings
The current study found evidence of profound weakness 
of both diaphragm and leg muscles at study entry, with 
both findings consistent with previous studies of muscle 
weakness in ICU patients [1–4, 7, 8]. The main finding 
of the present study, however, is that neither adminis-
tration of beta-hydroxy-beta-methylbutyrate (HMB) 
nor eicosapentaenoic acid (EPA) or the combination of 
both agents increased either diaphragm or quadriceps 
muscle strength or muscle thickness in mechanically 
ventilated medical ICU patients. Specifically, we found 
that administration of 10  days of these anabolic agents 
did not increase either diaphragm PdiTw or quadriceps 
muscle QuadTw levels in this patient cohort. In addition, 
the duration of mechanical ventilation was not altered 
by administration of HMB, EPA or HMB + EPA, with all 
experimental groups requiring the same time to be suc-
cessfully weaned from mechanical ventilator support.
Previous studies using HMB and EPA
The findings of the present study are surprising, since 
several previous manuscripts have reported improve-
ments in muscle strength in response to HMB and EPA 
in both cancer patients and in older adults [13–16]. In 
addition, HMB has been reported to appreciably reduce 
mortality when administered after discharge to patients 
with chronic lung and cardiac diseases [26]. One study 
also found that EPA administration to critically ill 
patients reduced the time required to wean patients from 
mechanical ventilation by 2 days [27]. In addition to these 
clinical reports, several animal studies have previously 
Fig. 4 Prescribed protein intakes, actual delivered protein intakes, 
and protein/kg/day are presented for the four experimental groups. 
The prescribed protein intake in grams was 94 (95% CI 85–103), 
78 (95% CI 65–91), 87 (95% CI 76–98), and 78 (95% CI 69–87), 
respectively for Control, EPA, HMB, and HMB + EPA groups (p = 0.086). 
The mean protein intake in grams was 78 (95% CI 68–88), 68 (95% 
CI 55–81), 76 (95% CI 65–87), and 66 (95% CI 57–75), respectively 
for Control, EPA, HMB, and HMB + EPA groups (p = 0.276). The mean 
protein intake in Gm/Kg was 0.96 (95% CI 0.84–1.08), 0.78 (95% CI 
0.62–0.94), 0.86 (95% CI 0.69–1.03), and 0.92 (95% CI 0.75–1.09), 
respectively for Control, EPA, HMB, and HMB + EPA groups (p = 0.373). 
As a result, there were no significant differences in protein intake 
(Kcal/Day) or protein intake normalized to body weight (Kcal/Kg) 
between the four groups
▸
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shown that HMB and EPA improve muscle function in 
animal models of illness [28, 29].
On the other hand, a recent study by Nakamura et al. 
[20] in which HMB was given to critical ill patients 
reported findings that are consistent with the findings 
in the present report. Specifically, Nakamura et  al. ran-
domized a group of critically ill patients to treatment 
with either routine nutrition or a nutritional regimen 
including 3 g/day of HMB, 14 g of arginine, and 14 g of 
glutamine daily for 10 days. These authors then examined 
the effects of these two nutritional regimens on femoral 
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Fig. 6 Change in quadriceps strength (QuadTw) between initial 
and post-treatment measurements is presented for the four 
experimental groups in the top panel (same format as in Fig. 5). The 
mean difference for quadriceps twitch force pre- and post-treatment 
was 2.26 (95% CI − 0.51 to 5.0), 1.12 (95% CI − 0.34 to 2.59), 0.26 
(95% CI − 3.01 to 3.57), and 0.18 (95% CI − 2.07 to 2.43), respectively, 
for Control, EPA, HMB, and HMB + EPA groups (p = 0.535). As a 
result, there was no significant difference in changes in quadriceps 
strength over time between the four experimental groups. Change 
in quadriceps thickness between initial and post-treatment 
measurements is presented for the four experimental groups in the 
bottom panel. The mean difference for quadriceps twitch thickness 
pre- and post-treatment was − 0.08 (95% CI − 0.39 to 0.23), − 0.33 
(95% CI − 0.77 to 0.11), − 0.34 (95% CI − 0.74 to 0.06), and − 0.15 
(95% CI − 0.58 to 0.27), respectively, for Control, EPA, HMB, and 
HMB + EPA groups (p = 0.647). As a result, there was no significant 
difference in changes in quadriceps thickness over time between the 
four experimental groups
Fig. 5 The change in diaphragm strength (PdiTw) between initial 
measurements and measurements made after drug treatment are 
presented for the four experimental groups in the top panel. Data 
is displayed as the log difference (y-axis) of pre- and post-treatment 
diaphragm twitch measurements for individual subjects included in 
the four experimental groups. The mean log difference for diaphragm 
twitch pressure (PdiTw) pre- and post-treatment was 0.18 (95% CI 
− 0.14 to 0.49), 0.09 (95% CI − 0.60 to 0.78), 0.31 (95% CI − 0.07 to 
0.68), and 0.12 (95% CI − 0.27 to 0.50), respectively, for Control, EPA, 
HMB, and HMB + EPA groups (p = 0.894). As a result, there was no 
significant difference in change of PdiTw over time between the 
four experimental groups. Change in diaphragm thickness between 
initial and post-treatment measurements is presented for the four 
experimental groups in the bottom panel. The mean log difference 
for diaphragm thickness pre- and post-treatment was − 0.01 (95% 
CI − 0.10 to 0.09), 0.04 (95% CI − 0.03 to 0.10), 0.04 (95% CI − 0.04 to 
0.13), and 0.01 (95% CI − 0.11 to 0.13), respectively, for Control, EPA, 
HMB, and HMB + EPA groups (p = 0.839). As a result, there was no 
significant difference in changes in diaphragm thickness over time 
between the four experimental groups
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muscle volume assessed with computerized tomography. 
This previous report found that HMB/arginine/glutamine 
complex supplementation did not inhibit muscle volume 
loss in critically ill patients. The current report extends 
these findings demonstrating that 10  days of treatment 
with HMB also does not improve quadriceps strength 
and, in addition, does not improve diaphragm strength or 
thickness, in critically ill MICU patients.
Potential role of physical therapy in modulating responses 
to HMB and EPA
There were, however, several limitations to the present 
study that may have compromised the ability of HMB 
and EPA to have salutary effects. All the patients in this 
study were to receive the standard paradigm of physi-
cal therapy applied to patients in the University of Ken-
tucky intensive care units. The hospital protocol calls for 
patients to be evaluated within 48  h of ICU admission 
and to then receive physical therapy 3 days per week for 
the duration of their ICU stays. In addition, patients also 
received occupational therapy, which included exercises 
for muscles in the upper body. Physical and occupational 
therapy sessions were cancelled, however, when patients 
were deemed too unstable to tolerate treatments or if 
ongoing nursing, diagnostic or therapeutic efforts pre-
vented patient exercise.
Because of these issues, only a small proportion of 
patients received anticipated daily durations of physi-
cal therapy (e.g. over 10  min of high quality physical 
and occupational therapy per day). In contrast, previous 
studies examining the effects of HMB and EPA in older 
adults and cancer patients included more intense exer-
cise training as a component of the therapeutic regimen 
[13–16]. In addition, previous animal studies using these 
agents did not limit physical activity [28, 29]. It therefore 
seems possible that HMB and EPA require some level of 
concomitant leg exercise to exert beneficial effects on leg 
muscle function and the low levels of physical therapy 
our patients received limited the effectiveness of these 
drugs to improve quadriceps strength or thickness.
On the other hand, there is no evidence that limb 
muscle exercise has any effect on diaphragm strength 
or thickness in MICU patients. In addition, no previous 
study has examined the effects of either HMB or EPA on 
diaphragm strength or thickness in any patient popula-
tion. As a result, there is also no reason to believe that 
reductions in the provision of physical therapy in the pre-
sent study limited the effectiveness in HMB and/or EPA 
to improve diaphragm parameters.
Potential role of timing and dosage of treatment with HMB 
and EPA
Another factor that may have compromised the ability of 
HMB and EPA to impact muscle function in the current 
study is the timing of drug administration. In previous 
studies employing animal models of disease (e.g. sepsis), 
HMB and EPA were administered soon after the induc-
tion of sepsis [28, 29]. These reports found that these two 
agents were capable of preventing the development of 
sepsis induced muscle dysfunction but did not determine 
if administration of these agents at late time points after 
the induction of weakness resulted in reversal of mus-
cle dysfunction. There are reasons to believe, moreover, 
that the processes responsible for the induction of criti-
cal care related muscle dysfunction may be quantitatively 
and qualitatively different from the factors that result in 
a failure of muscles to recover [30]. For example, muscle 
protein synthesis declines early after the induction of sep-
sis but later increases to supra-normal levels [36]. HMB 
is known to prevent phosphorylation of eiF2α [31] and 
may thereby block the early sepsis induced reductions in 
protein synthesis, but, theoretically, this action should not 
be effective in improving muscle function if HMB is given 
well after muscle weakness has developed. In the present 
work, patients were often recruited into the study days 
after they became sick, with patients receiving an aver-
age of 6 days of mechanical ventilation before study entry. 
Moreover, the vast majority of patients were profoundly 
weak at the time of the initial measurements, again argu-
ing that a significant time had elapsed between the insult 
inducing muscle injury and the time that therapies were 
given. It is possible that this delay prevented these agents 
from having beneficial effects. On the other hand, it is also 
Fig. 7 The duration of mechanical ventilation after randomization 
to treatment is presented for the four experimental groups using 
the format in Fig. 2. The mean log of mechanical ventilation duration 
was 1.63 (95% CI 1.10–2.15), 2.05 (95% CI 1.59–2.51), 2.03 (95% CI 
1.57–2.49), and 1.71 (95% CI 1.38–2.05), respectively, for Control, EPA, 
HMB, and HMB + EPA groups (p = 0.372). There was no significant 
difference in the time required to wean patients from mechanical 
ventilation between the four experimental groups
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important to point out that all the arguments presented in 
the previous paragraph are based on extrapolations from 
studies done in non-ICU patients or animals. The ideal 
timing of administration of HMB, EPA, or other anabolic 
agents to MICU patients is completely unknown.
One might also ask if a higher dose of HMB or EPA or 
a different route of administration of these agents might 
have elicited a positive response. The HMB and EPA 
doses used in this study are standard doses used in many 
previous studies in which these agents were found to have 
a beneficial effect on muscle function. While a few stud-
ies have used higher doses of HMB than 3 g/day, there is 
no convincing evidence that higher doses are more effec-
tive in improving muscle function. The enteral route of 
administration of these agents has also been used in the 
vast majority of human studies examining the effects of 
these agents on muscle [20]. In fact, a large percentage 
of enteral formulations used to feed ICU patients contain 
HMB, EPA, or both, and it has been assumed by major 
manufacturing companies that this route of administra-
tion is adequate to deliver these agents to achieve thera-
peutic effects. The current findings raise the possibility 
that these assumptions may be incorrect. It is possible 
that absorption of these agents may have been impaired 
in our extremely ill patient population, limiting the effec-
tiveness of these agents to improve muscle function.
Number of patients studied
The number of patients recruited into this study was 
based on a prior sample size calculation that estimated 
18 patients per group, for a total of 72 patients enrolled, 
would be required to detect an increase in muscle 
strength in response to one of the treatments being stud-
ied (HMB or EPA). One might ask if a statistically signifi-
cant response would have been detected had we studied 
more patients. Increasing the number of patients studied, 
however, would not be expected to change the magnitude 
of the increases observed over time in the various experi-
mental groups or the variance of the strength meas-
urements. Inspection of our data reveals that, at best, 
diaphragm twitch pressure increased by only 2  cm H20 
in any of the four experimental groups and quadriceps 
twitch force increased only 2 Newtons in the four experi-
mental groups after 10 days of therapy. We believe incre-
ments of this magnitude are insufficient to alter patient 
outcomes. One might argue that had we studied many 
more patients, we might have proven that these incre-
ments may be statistically significant, but they would 
remain clinically irrelevant.
Persistence of quadriceps and diaphragm weakness
The failure of the therapies in the current study while disap-
pointing, does not, however, diminish the importance of 
skeletal muscle weakness as a risk factor for poor outcomes in 
critically ill, mechanically ventilated patients. Previous work 
indicates that diaphragm twitch pressures less than 8 cm  H2O 
are associated with an extremely high mortality and a pro-
tracted requirement for mechanical ventilation [1–4]. The vast 
majority of patients in the current study, i.e. 86%, had PdiTw 
levels less than 8 cm  H2O at the time of study inclusion and 
therefore fell into this high-risk category. In addition, PdiTw 
levels did not increase significantly in any treatment group 
and at the end of study treatment administration (i.e. 10 days); 
85% of all patients still manifested PdiTw levels less than 8 cm 
 H2O. This finding indicates that diaphragm function did not 
substantially improve over time in any of the patients in the 
study and remained dangerously low. Similarly, the majority 
of patients had extremely low quadriceps twitch pressures, 
with 85% having a QuadTw value less than 6 Newtons at 
study inclusion. Like diaphragm function, quadriceps strength 
did not improve over time in any group and the majority of 
patients (85%) had QuadTw levels less than 6 Newtons after 
the period of study drug administration, i.e. 10 days.
Implications for future clinical trials with anabolic agents
Physical therapy remains the one established approach to 
try to improve muscle function and patient outcomes in 
ICU patients. There are even limitations to this approach, 
and early intensive physical therapy, termed early mobi-
lization, does not appear to benefit patients more than 
standard physical therapy [32].
Unfortunately, there are also no established adjunctive 
forms of therapy that are clearly capable of eliciting major 
improvements in the strength of either the quadriceps or 
diaphragm in critically ill patients. While some work sug-
gests that use of NMES (neuromuscular electrical stimu-
lation) may improve quadriceps strength, other studies 
indicate these effects are small [33–35]. In addition, while 
inspiratory muscle training has been used to improve dia-
phragm function in some studies of mechanically venti-
lated patients, other studies found this treatment did not 
improve outcomes [36, 37]. Diaphragm pacing is another 
form of treatment that has been postulated to increase dia-
phragm strength and improve outcomes, but this therapy 
will require substantial clinical trial testing before it can be 
assumed that this is an effective treatment [38, 39]. In addi-
tion, to our knowledge, there are no studies that have estab-
lished the utility of administration of any pharmacological 
therapies to improve muscle strength in ICU patients.
The current findings, therefore, reinforce the need 
for additional therapeutic trials to prevent and reverse 
skeletal muscle dysfunction in critically ill patients. 
Importantly, the failure of the current study to iden-
tify a successful treatment provides some guidance for 
the design of future trials in order to avoid the pitfalls 
observed in the present report.
Page 13 of 14Supinski et al. Crit Care          (2021) 25:308  
First, we believe additional basic science research is 
needed to more fully determine the cellular mechanisms 
by which disease processes reduce muscle function in the 
critically ill. Multiple processes interact to reduce muscle 
function in this population including systemic inflamma-
tion, inactivity, alterations secondary to nutritional defi-
ciencies, and muscle damage due to aberrant contraction 
patterns. Therapies which may be effective in treating one 
of these processes (increased muscle contraction to coun-
teract inactivity) may be ineffective in treating other pro-
cesses (e.g. inflammation) or may worsen muscle function 
for other processes (e.g. aberrant muscle contraction). Sec-
ond, based on current understanding, future clinical stud-
ies should mandate structured respiratory and limb muscle 
physical training regimens of at least moderate intensity as 
a component of treatment protocols. Third, it is reasonable 
to believe most anabolic agents should be administered at 
an early time point (e.g. within 48 h of the onset of critical 
illness) to prevent the potential irreversible loss of muscle 
reparative elements. Fourth, anabolic agents need to be 
developed that facilitate muscle recovery/repair for use in 
clinical trials studying patient populations with pre-exist-
ing severe muscle weakness. Identification of such agents 
and conduct of such future trials is urgently needed to 
develop an effective treatment to prevent the devastating 
acute and long-term consequences of critical care induced 
diaphragm and limb muscle dysfunction.
Conclusions
These results indicate that HMB and EPA did not 
improve skeletal muscle strength in medical ICU patients 
when given as a 10 day course. This finding is mitigated, 
however, by the fact that many of the ICU patients in this 
study were too unstable to receive planned durations of 
daily physical therapy and it is possible that responses to 
medications may have been better if more physical ther-
apy could have been provided. No one knows, however, 
exactly how much physical therapy is needed to improve 
the response of ICU patients to nutritional supplements. 
This important issue needs to be studied in detail in 
future clinical trials.
The findings of this study also confirm previous reports 
that diaphragm and leg strength of medical ICU patients 
are profoundly low, emphasizing the need for additional 
therapeutic trials to prevent and reverse skeletal muscle 
dysfunction in critically ill patients. It is hoped that the les-
sons learned from the current study will help investigators 
in the design of future clinical trials to examine the effects 
of other anabolic agents and innovative forms of physical 
therapy on skeletal muscle function in critically ill patients.
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